|
|
Is The mRNA Payload The Real MVP Of Targeted Delivery? | By Anna Rose Welch, editorial & community director, Advancing RNA | As one delightfully colorful quote from a panel discussion at the AMM Ascent meeting last fall reminds us, there’s a lot more to be explored, discussed, and understood as it relates to the mRNA cargo’s role in targeted delivery. |
|
|
|
By Erin Harris, editor-in-chief, Cell & Gene | Tessera Therapeutics' CSO, Michael Holmes, Ph.D., shares information on the company's Gene Writers for sickle cell disease (SCD) and how their work has garnered investment from the Bill & Melinda Gates Foundation to support their efforts. | |
|
|
|
|
|
| The 4th Circular & Self-Amplifying RNA Therapeutics Summit is returning this May to unite leading next-generation RNA stakeholders, including the likes of Sail Biomedicines, Merck, Novo Nordisk, and more. This is the only industry-dedicated event showcasing the latest approaches and applications for more potent and durable treatment of a wide array of diseases to gain actionable insights for fast-tracking your RNA programs. |
|
|
|
|
|
|
|
|
|
|
.png){kind=logo}
